NuvaRing Lawsuit: Hold the Manufacturer Accountable for the Negative Side Effects

If you’re wondering how the manufacturer of the NuvaRing was allowed to formulate and sell a contraceptive with known high-risk hormone levels, you’re not alone. If you are a current or former the NuvaRing user who has experienced any side effects related to blood clotting, please give our dangerous drug attorneys in New York, NY, a call. Douglas & London is ready to handle your NuvaRing lawsuit and protect your rights.

The NuvaRing is a prescription birth control device designed to prevent pregnancy through the controlled release of estrogen and progesterone hormones into the bloodstream. Women manually insert the small, flexible vaginal ring once a month for three weeks to prevent conception. Approved by the FDA in 2001, the NuvaRing has been one of the most popular forms of birth control devices, with over a million women throughout the U.S. using the contraception.

Unfortunately, what was marketed by Organon and later bought by Merck (formerly Schering-Plough Corp.) as a safe and simple birth control device has since been linked to serious side effects. The main culprit is the NuvaRing's third-generation desogestrel progestin component known as etonogestrel, which at high levels delivered directly into the bloodstream can cause dangerous blood clotting issues and related health conditions. Side effects from this NuvaRing hormone may include: 

  • Blood clots
  • Cardiovascular accidents
  • Cerebral hemorrhaging
  • Heart attacks
  • Myocardial infarction
  • Pulmonary embolism
  • Strokes

Since 1995, studies have revealed that birth control containing desogestrel caused an elevated risk for dangerous blood clots compared to previous forms using other types of progestins.

In October 2003, The New England Journal of Medicine addressed research suggesting that birth control containing desogestrel can significantly increase the risk of blood clots.

Additionally, in 2011 the FDA released its new drug-safety study report, “Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints”, which included the NuvaRing.

The FDA study found that the NuvaRing was associated with a significantly higher risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) relative to standard low-dose estrogen birth control pills. It went on to state that continuous exposure to combined hormonal contraceptives such as the NuvaRing could potentially result in higher sustained exposure to estrogen and hence, increased thromboembolic risk.

Contact Us

"Since the inception of the firm, Douglas & London has taken the opportunity to give back to the community. It is a right, a privilege and a responsibility our firm takes very seriously. We fully understand that without community, there’s no Douglas & London."

-- The Team at Douglas & London


New York Office

59 Maiden Ln
6th Floor
New York, NY 10038

Closed Today


Contact Us